| Outcome Measures: |
Primary: Absolute change in HbA1c between both placebo and rimonabant group., From baseline to week 48|Percentage of participants reaching the treat-to-target objective of HbA1c ≤ 6.5% and ≤ 7.0%, From the beginning to the end of the study|Percentage of participants responding to treatment, From the beginning to the end of study|Rate of asymptomatic, symptomatic, and severe hypoglycaemia, From the beginning to the end of the study|Change in physical examinations, vital signs, laboratory parameters, adverse events, From the beginning to the end of the study | Secondary: Change in insulin sensitivity, fasting plasma glucose, hypoglycaemia rate., From the beginning to the end of the study|Change in BMI, waist and hip circumference, waist/hip ratio, weight, From the beginning to the end of the study|Changes in Quality of Life, From the beginning to the end of the study|Change in lipid measures: HDL (High Density Lipoprotein), LDL (Low-Density Lipoprotein), TG (Triglycerides), TC (Total Cholesterol), ApoB (Apolipoprotein B), From administration of drug till end of study|Change in adiponectin, fasting insulin, Blood Pressure, concomitant medications, health resource use, CRP (C Reactive Protein), ALT (Alanine Aminotransferase), albumin/creatinine ratio, From administration of drug to end of study
|
